You are here

Cosentyx Improves Psoriatic Arthritis in Three-Year Study

Seventy-seven percent of subjects achieve ACR20 response

New data have shown that secukinumab (Cosentyx, Novartis) delivered sustained improvements in the signs and symptoms of psoriatic arthritis (PsA)––including patient-reported pain––during three years of treatment.

Secukinumab is the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate three-year efficacy in patients with PsA, a life-long inflammatory disease that affects the skin and joints. Secukinumab is also the only IL-17A inhibitor indicated for PsA, ankylosing spondylitis (AS), and psoriasis, which is significant, according to Novartis, as up to 80% of patients diagnosed with PsA already have psoriasis.

In the first year of the three-year open-label extension study, which was a continuation of a two-year double-blind trial, 77% of PsA patients achieved at least 20% improvement in American College of Rheumatology response criteria (ACR20) with secukinumab. Most of the patients (95%) completed the first year of the extension trial. The new data showed that response rates were consistent from year 1 (69.4%) to year 3 (76.8%) and that this was independent of whether patients received anti-tumor necrosis factor (TNF) therapy before being treated with secukinumab.

The components of the ACR response criteria include patient-reported pain. Previously, 79% of secukinumab-treated AS patients had achieved an ASAS20 response (Assessment of Spondyloarthritis International Society response criteria) at two years. Previous data also showed that up to 80% of AS and 84% of PsA patients treated with secukinumab at two years had no radiographic progression in the spine or joints, respectively.

In addition, analyses using matching-adjusted indirect comparison (MAIC) showed that secukinumab may improve the signs and symptoms of AS and PsA more than adalimumab (Humira, AbbVie). In a new MAIC for AS, the ASAS20 response rates at week 52 were higher for secukinumab (74%) than for adalimumab (65%). Likewise, in the MAIC for PsA patients, ACR20 response rates at week 48 were higher for secukinumab (72%) than for adalimumab (56%). 

Novartis plans to initiate new head-to-head clinical trials to directly compare secukinumab with adalimumab in patients with AS and PsA. These studies will include a total of 850 patients and will be the first adequately powered head-to-head studies with biologic medications to differentiate treatment efficacy in these diseases.

Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A. It is the first IL-17A inhibitor approved for the treatment of patients with active AS and PsA in the United States.

Source: Novartis; November 14, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs